EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cocrystal Pharma's Enterprise Value is $-8.68 Mil.
Cocrystal Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-14.78 Mil. Therefore, Cocrystal Pharma's EV-to-FCF for today is 0.59.
The historical rank and industry rank for Cocrystal Pharma's EV-to-FCF or its related term are showing as below:
COCP'
s EV-to-FCF Range Over the Past 10 Years
Min: -168.11 Med: -8.63 Max: 4.06
Current: 0.59
During the past 13 years, the highest EV-to-FCF of Cocrystal Pharma was 4.06. The lowest was -168.11. And the median was -8.63.
COCP's EV-to-FCF is ranked better than 72.34% of 394
companies
in the Biotechnology industry
Industry Median: 4.23
vs COCP: 0.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Cocrystal Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cocrystal Pharma's EV-to-FCF
For the Biotechnology subindustry, Cocrystal Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cocrystal Pharma's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cocrystal Pharma's EV-to-FCF falls into.
Cocrystal Pharma's current Enterprise Value is $-8.68 Mil.
Cocrystal Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cocrystal Pharma (NAS:COCP) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cocrystal Pharma's PE Ratio for today is calculated as:
Cocrystal Pharma's share price for today is $1.555.
Cocrystal Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cocrystal Pharma EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Cocrystal Pharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Cocrystal Pharma (Cocrystal Pharma) Business Description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COCP has been successfully added to your 